Clausena anisata-mediated protection against lipopolysaccharide-induced acute lung injury in mice

CHAN-MI JEON1,2, IN-SIK SHIN1,3, NA-RAE SHIN1, JU-MI HONG1, OK-KYOUNG KWON1, JUNG-HEE KIM1, SEI-RYANG OH1, TRAN-THE BACH1, DO-VAN HAI3, BUI-HONG QUANG1, SANG-HO CHOI3, JOONGKU LEE5,6, PYUNG-KEUN MYUNG2 and KYUNG-SEOP AHN1

1Natural Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology, Cheongwon-gu, Cheongju-si, Chungcheongbuk-do 34116; 2College of Pharmacy, Chungnam National University, Yuseong-gu, Daejeon, Chungcheongnam-do 34134; 3College of Veterinary Medicine, Chonnam National University, Buk-gu, Gwangju 500-757, Republic of Korea; 4IEBR, Vietnam Academy of Science and Technology (VAST), Cay Giay, Ha Noi, Vietnam; 5International Biological Material Research Center, Korea Research Institute of Bioscience and Biotechnology, Yuseong-gu, Daejeon 34141; 6Department of Environment and Forest Resources, Chungnam National University, Daejeon 34134, Republic of Korea

Received February 11, 2015; Accepted February 26, 2016

DOI: 10.3892/ijmm.2016.2515

Abstract. Clausena anisata (Willd.) Hook.f. ex Benth. (CA), which is widely used in traditional medicine, reportedly exerts antitumor, anti-inflammatory and other important therapeutic effects. The aim of the present study was to investigate the potential therapeutic effects of CA in a mouse model of lipopolysaccharide (LPS)-induced acute lung injury (ALI) and in LPS-stimulated RAW 264.7 cells. Male C57BL/6 mice were administered treatments for 3 days by oral gavage. On day 3, the mice were instilled intranasally with LPS or PBS followed 3 h later by oral CA (30 mg/kg) or vehicle administration. In vitro, CA decreased nitric oxide (NO) production and pro-inflammatory cytokines, such as interleukin (IL)-6 and prostaglandin E2 (PGE2), in LPS-stimulated RAW 264.7 cells. CA also reduced the expression of pro-inflammatory mediators, such as cyclooxygenase-2. In vivo, CA administration significantly reduced inflammatory cell numbers in the bronchoalveolar lavage fluid (BALF) and suppressed pro-inflammatory cytokine levels, including tumor necrosis factor-α (TNF-α), IL-6, and IL-1β, as well as reactive oxygen species production in the BALF. CA also effectively reduced airway inflammation in mouse lung tissue of an LPS-induced ALI mouse model, in addition to decreasing inhibitor κB (IκB) and nuclear factor-κB (NF-κB) p65 phosphorylation. Taken together, the findings demonstrated that CA inhibited inflammatory responses in a mouse model of LPS-induced ALI and in LPS-stimulated RAW 264.7 cells. Thus, CA is a potential candidate for development as an adjunctive treatment for inflammatory disorders, such as ALI.

Introduction

Acute lung injury (ALI) is the basis of acute respiratory distress syndrome (ARDS) and is involved in the development of multiple organ failure, which leads to death in patients with sepsis, shock and pneumonia (1-3). ALI is characterized by neutrophil accumulation in the lung, lung tissue destruction, lung edema and diffuse lung inflammation, which is accompanied by the overexpression of inflammatory mediators, including cytokines and chemokines. The search for an effective ALI therapy has been ongoing for decades. However, there are few effective therapies for ALI (4,5). Therefore, it is essential to develop novel effective therapies for ALI.

Lipopolysaccharide (LPS), a constituent of the outer membrane of gram-negative bacteria, is a key pathogen in animal models of ALI (9,10). Previous studies have reported that LPS induces direct/indirect neutrophil and macrophage activation, resulting in the release of pro-inflammatory mediators (11,12). This cascade eventually aggravates inflammatory responses on various lesions that have been damaged by stimuli. Previous findings have demonstrated that LPS exerts its inflammatory responses by activating specific inflammatory signaling pathways, such as the nuclear factor-κB (NF-κB) signaling pathway. NF-κB, a central regulator of inflammation, and the NF-κB signaling pathway are considered to be involved in the pathogenesis of ALI. Once NF-κB is activated, NF-κB signaling proceeds through phosphorylation and the subsequent phosphorylation and degradation of the inhibitor of κB (IκB),
resulting in the cytoplasmic release and nuclear translocation of NF-κB (13,14). Thus, NF-κB activation induces the transcription of pro-inflammatory mediators. These mediators include tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6, cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) (15-18), which play critical roles in ALI (12). Thus, NF-κB is a potential therapeutic target in ALI.

_Clausena anisata_ (Willd.) Hook.f. ex Benth. (CA), locally known as ‘isifudu’ in the South African isiZulu language, is widely used in traditional medicine to treat many diseases. Various parts of CA, such as leaves, roots and bark, are reportedly useful as effective remedies against parasitic infections, eye complaints, heart disorders, hypertension, constipation, gastroenteritis, malaria, other febrile conditions, other inflammatory conditions, toothaches, swollen gums, mental disorders, impotence and sterility (19-25).

However, the anti-inflammatory effect of CA has yet to be studied in ALI. Thus, the present study aimed to evaluate the effects of CA, and to elucidate the underlying mechanisms of action of CA, in a mouse model of LPS-induced ALI and in LPS-stimulated RAW 264.7 cells.

**Materials and methods**

_Preparation of plant extract. Clausena anisata_ (Willd.) Hook.f. ex Benth. of the family Rutaceae was collected from Ninh Thuan province, Thuan Bac district, Cong Hai, Vietnam. Plant samples were identified by Tran-The Bach, Institute of Ecology and Biological Resources. Voucher specimens (KRIB 0034836,7,8) have been deposited in the herbarium of Ecology and Biological Resources. Voucher specimens (5, 10, 20 and 40 µg/ml). CA was obtained from the Plant Extract Bank at the Korea Research Institute of Bioscience and Biotechnology (KRIBB) (BVN12106; Daejeon, Korea).

_In vitro experiment_ 

_Cel l culture_. RAW 264.7 macrophages were maintained at 1x10^6 cells/ml in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (both from Sigma-Aldrich, St. Louis, MO, USA) and 1% (w/v) antibiotic-antimycotic solution (Invitrogen, Grand Island, NY, USA) in a 95% air and 5% CO₂, humidified atmosphere at 37°C. The cells were seeded in 96-well plates at 5x10⁴ cells/well and incubated in serum-free medium in the presence of different CA concentrations (5, 10, 20 and 40 µg/ml). CA was obtained from the Plant Extract Bank at the Korea Research Institute of Bioscience and Biotechnology (KRIBB) (BVN12106; Daejeon, Korea).

_Cel l viability assay_. Cell viability was evaluated by determining the mitochondrial reductase function using with an assay based on the reduction of tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (CAS#298-93-1; Amresco, LLC, Solon, OH, USA) into formazan crystals. Formazan formation is proportional to the number of functional mitochondria in living cells. To determine cell viability, 50 mg/ml of MTT was added to 5 µl of cell suspension (1x10⁵ cells/ml in 96-well plates) for 4 h. The formazan formed was dissolved in acidic 2-propanol, and the optical density was measured at 570 nm using a microplate reader (Benchmark; Bio-Rad Laboratories, Inc., Hercules, CA, USA). The optical density of formazan formed in the control (untreated) cells was set to 100% viability.

_Measurement of nitric oxide (NO) production_. NO production in RAW 264.7 cell culture supernatants was determined using the Griess reaction. The cells were incubated in the presence of LPS (0.5 µg/ml) at 37°C for 24 h. The cells were then dispensed into 96-well plates, and 100 µl of each supernatant was mixed with the same volume of Griess reagent (% sulfanilamide, 0.1% N-(1-naphthyl)-ethylenediamine dihydrochloride and 5% phosphoric acid) and agitated gently for 10 min at room temperature. The nitrite concentration was measured at 540 nm using sodium nitrite to generate a standard curve.

_Measurement of PGE₂ and pro-inflammatory cytokine production_. Cultures were serum-starved for 24 h and treated with experimental agents. Following culture incubation under experimental conditions, the media from each sample were collected and assessed for IL-6 synthesis using a commercial enzyme-linked immunosorbent assay (ELISA) (R&D Systems, Inc., Minneapolis, MN, USA) according to the manufacturer's protocol, and the assay was calibrated spectrophotometrically with a standard curve. Supernatant PGE₂ levels were determined using a PGE₂ enzyme immuno assay (EIA) kit (Cayman Chemical Co., Ann Arbor, MI, USA) according to the manufacturer's protocol.

_Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)_ . Total RNA was reverse transcribed using AccuPower RT Premix (Bioneer Corporation, Daejeon, Korea) according to the manufacturer's instructions. The resulting cDNA (equivalent to 40 ng total RNA) was used for qPCR using FirstStart DNA MasterPLUS SYBR-Green I and LightCycler (both from Roche Diagnostics, Indianapolis, IN, USA) according to the manufacturer's instructions. qPCR was performed using the primers: COX-2, sense, 5'-GAA GTC TTT GGT CTG GTG GCC TG-3'; and antisense, 5'-GTC TGC TGG TTT GGA ATA GTT GC-3'; and β-actin sense, 5'-CCG TCA TTG CGG CCG ATA GTG AT-3' and antisense, 5'-TGT TGG TGG CCT TCA ACA CC-3'. All of the samples were normalized to β-actin. qPCR products were subjected to electrophoresis on 1.5% agarose gels and stained with ethidium bromide. Images were captured with an Olympus C4000 zoom camera system (Olympus America Inc., Melville, NY, USA).

_Western blot analysis_. Cells (1x10⁶) were harvested and washed twice in cold Tris-buffered saline (TBS). The cells were solubilized in ice-cold 1% Triton X-100 lysis buffer. After 30 min on ice, the lysates were clarified by centrifugation at 600 x g for 20 min. Proteins (20 µg) were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (10% acrylamide) and transferred to nitrocellulose membranes. The membranes were incubated with blocking solution (5% skim milk) and then incubated overnight at 4°C with the appropriate primary antibodies. The primary antibodies and dilutions used were: anti-β-actin (1:2,000 dilution; Cat. no. P06709; Cell Signaling Technology, Inc., Beverly, MA, USA) and anti-COX-2 (1:1,000 dilution; Cat. no. SC-1745; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). The membranes were washed three times with TBS containing Tween-20 (TBST) and then incubated with a 1:3,000 dilution of horseradish peroxidase (HRP)-conjugated secondary antibodies.
In vivo experiment

Animals. Male C57BL/6 mice (6-8 weeks of age) were obtained from Orient Co. (Seoul, Korea). The mice were provided with food and water ad libitum in an animal facility at a temperature of 22-24 °C and on a 12 h light/dark cycle under specific pathogen-free conditions. The mice were housed for a minimum of one week for environmental adaptation prior to experimentation. Experimental procedures were approved by the Institutional Animal Care and Use Committee of the Korea Research Institute of Bioscience and Biotechnology.

LPS-induced ALI in mice. Specific pathogen-free male C57BL/6 mice were randomly divided into four groups (n=7/group): i) NC (normal control); ii) LPS (LPS treatment); iii) Dex (LPS treatment + oral gavage of 5 mg/kg dexamethasone for 3 days); and iv) CA (LPS treatment + oral gavage of 30 mg/kg CA for 3 days). The mice from the control and LPS groups received an equal volume of phosphate-buffered saline (PBS) instead of dexamethasone or CA. Three hours after drug administration on the third day, the mice were slightly anesthetized with diethyl ether inhalation, and 10 µg of LPS in 50 µl of PBS was instilled intranasally (i.n.) to induce lung injury. The mice in the control group were given 50 µl of PBS without LPS. Twenty-four hours after the LPS treatment, the mice were sacrificed by an i.p. injection of pentobarbital (50 mg/kg; Hanlim Pharm. Co. Ltd., Seoul, Korea) and bronchoalveolar lavage fluid (BALF) and lung tissue samples were harvested for further studies.

BALF collection and cell counting. BALF collection was performed three times through a tracheal cannula with autoclaved PBS and instilled up to a total volume of 1.4 ml. The BALF was centrifuged at 200 x g for 15 min at 4°C. Following centrifugation, the supernatant was stored at -70˚C for subsequent cytokine assays. The total inflammatory cell numbers were assessed by counting cells in at least five squares of a hemocytometer after excluding dead cells by trypan blue staining. To determine differential cell counts, 100 µl of BALF was centrifuged onto slides using a Cytospin (Hanil Science Industrial, Seoul, Korea). After the slides were dried, the cells were fixed and stained using Diff-Quik<sup>®</sup> staining reagent (B4132-1A; IMEB Inc., Deerfield, IL, USA).

Measurement of reactive oxygen species (ROS). Detection of cellular ROS in inflammatory cells was performed using 2',7'-dichlorofluorescein diacetate (DCF-DA) reagent as part of a kit purchased from Abcam (ab112851; Cambridge, MA, USA). After cell counting, 100 µl of inflammatory cells were seeded in 96-well plates. The cells were stained with 20 µM DCFDA for 30 min at 37°C. Fluorescence intensity was then measured at 485 nm excitation and 530 nm emission using a microplate reader (Bio-Rad Laboratories, Inc.).

Measurement of cytokine levels in BALF. TNF-α, IL-1β and IL-6 levels in BALF were measured using ELISA kits (BioSource International, Camarillo, CA, USA). The procedures were performed according to the manufacturer's instructions.

Histopathological lung examination. After obtaining the BALF samples, lung tissue was fixed in 10% (v/v) neutral-buffered formalin. Lung tissues were embedded in paraffin, cut into 4-µm sections, and stained with hematoxylin and eosin (H&E) solution (both from Sigma-Aldrich; hematoxylin, MHS-16; eosin, HT110-1-32) to estimate inflammation.

Western blot analysis. Lung tissues were harvested and homogenized (1/10 w/v) using a homogenizer and tissue lysis/extraction reagent containing a protease inhibitor cocktail (both from Sigma-Aldrich). Protein concentrations were determined using a Bradford reagent (Bio-Rad Laboratories, Inc.). Western blotting was performed as described above, and the following primary antibodies and dilutions used were: anti-IκB (1:1,000 dilution; Cell Signaling Technology, Inc.), anti-NF-κB p65 (1:1,000 dilution; Santa Cruz Biotechnology, Inc.) and anti-β-actin (1:2,000 dilution; Cell Signaling Technology, Inc.).

Images captured and photomicrography. The photomicrographs were obtained using a Photometric Quantix digital camera running Windows, and images were assembled in Adobe Photoshop 7.0. Images were cropped and corrected for brightness and contrast but were not otherwise manipulated.

Statistical analysis. Data were presented as the means ± standard error of the mean (SEM). Statistical significance was determined using analysis of variance (ANOVA) followed by a multiple comparison test with Dunnett's adjustment. P<0.05 was considered to indicate a statistically significant difference.

Results

In vitro evaluation

Effects of CA on NO production in LPS-stimulated RAW 264.7 cells. Non-toxic CA concentrations (5, 10, 20 and 40 µg/ml) (Fig. 1A) were assessed for their ability to inhibit LPS-stimulated NO production. NO production was significantly increased in LPS-stimulated RAW 264.7 cells. By contrast, CA at 20 and 40 µg/ml induced a significant decrease in LPS-induced NO production; NO production decreased in a concentration-dependent manner (Fig. 1B).

Effect of CA on PGE<sub>2</sub> and pro-inflammatory cytokine production in LPS-stimulated RAW 264.7 cells. PGE<sub>2</sub> levels in the culture supernatant increased with LPS stimulation, and this effect was markedly reduced by CA treatment (Fig. 2A). Treatment of RAW 264.7 cells with LPS alone resulted in a significant increase in IL-6 production compared with the control group (Fig. 2B). However, CA treatment significantly inhibited LPS induction of IL-6, in a dose-dependent manner.

Effect of CA on mRNA and protein expression levels of inflammatory mediators. COX-2 mRNA and protein production was significantly increased in LPS-stimulated RAW 264.7 cells (Fig. 3). However, CA-treated cells exhibited significantly decreased COX-2 mRNA and protein levels compared with LPS-stimulated cells in a concentration-dependent manner.

In vivo experiment

Effect of CA on inflammatory cell counts in the BALF isolated from mice with LPS-induced ALI. The total number of inflammatory cells in the BALF comprised neutrophils, macrophages and lymphocytes. LPS challenge significantly increased the
Figure 1. Effects of C. anisata (CA) on cell viability and the production of nitric oxide (NO) in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells. The cells were treated with different concentrations (5, 10, 20 and 40 µg/ml) of CA for 1 h, and then incubated in the presence of LPS (0.5 µg/ml) for 24 h. (A) Cell viability, (B) NO production. Significantly different from the control, *P<0.05; significantly different from the cells treated with LPS alone, †P<0.05; significantly different from the cells treated with LPS alone, ‡P<0.01.

Figure 2. C. anisata (CA) reduces production of prostaglandin E2 (PGE2) and a pro-inflammatory cytokine in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells. (A) PGE2 levels and (B) interleukin (IL)-6 levels. The cytokine levels were determined using an enzyme-linked immunosorbent assay (ELISA). Absorbance was measured at 450 nm using a microplate reader. Significantly different from the control, *P<0.05; significantly different from the cells treated with LPS alone, †P<0.05; significantly different from the cells treated with LPS alone, ‡P<0.01.

Figure 3. C. anisata (CA) reduces the expression of cyclooxygenase-2 (COX-2) in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells. (A) mRNA expression of COX-2 determined by RT-qPCR using β-actin as the internal control. (B) Protein expression levels of COX-2 determined by western blot analysis using β-actin as the internal control. Significantly different from the control, *P<0.05; significantly different from the cells treated with LPS alone, †P<0.01.
The number of total cells, neutrophils, macrophages and lymphocytes compared with the control group. However, BALF samples from the CA-treated mice exhibited a significantly decreased influx of total cells, neutrophils, macrophages and lymphocytes compared with the LPS-treated mice (Fig. 4). The reductions were similar to the results obtained in the dexamethasone-treated mice.

**Effect of CA on ROS production in the BALF isolated from mice with LPS-induced ALI.** ROS levels in the BALF were significantly increased in LPS-treated mice compared with the normal control group (Fig. 5). By contrast, the CA-treated mice exhibited reduced ROS production compared with the LPS-treated mice. The reductions were similar to the results obtained in the dexamethasone-treated mice.

**Effect of CA on pro-inflammatory cytokine production in the BALF isolated from mice with LPS-induced ALI.** TNF-α, IL-1β and IL-6 levels in the BALF were significantly increased in LPS-treated mice compared with the negative control group (Fig. 6). By contrast, CA-treated mice exhibited a significant decrease in TNF-α, IL-1β and IL-6 levels compared with the LPS-treated mice. The reductions were similar to the results obtained in the dexamethasone-treated mice.

**Effects of CA on the inflammatory response in the lung tissue of mice with LPS-induced ALI.** To evaluate histological changes following LPS treatment of LPS-induced lung inflammation, the lung sections were subjected to H&E staining.
Significant pathological changes were observed in the lungs of LPS-treated mice including inflammatory cell infiltration, lung tissue damage, and alveolar wall thickening. However, fewer histopathological changes were observed in the lung tissues of CA-treated mice compared with the LPS-treated mice (Fig. 7). The reductions were similar to the results obtained in the dexamethasone-treated mice.

**Discussion**

CA is a traditional medicine that is widely used for its reported antitumor and anti-inflammatory activities (19-25). The aim of the present study was to investigate the potential therapeutic effects of CA in a mouse model of LPS-induced ALI and in LPS-stimulated RAW 264.7 cells. *In vitro*, CA decreased NO production and pro-inflammatory cytokines, such as IL-6, as well as PGE₂ in LPS-stimulated RAW 264.7
cells. CA also reduced the expression of pro-inflammatory mediators such as COX-2. In vivo, CA-treated mice had significantly reduced inflammatory cell counts in the BALF and suppressed pro-inflammatory cytokine levels, including TNF-α, IL-6 and IL-1β, as well as decreased production of ROS in the BALF. CA effectively reduced airway inflammation in the lung tissue, in addition to decreasing IκB and NF-κB p65 phosphorylation, compared with the LPS-treated mice.

Previous studies have demonstrated that LPS stimulates alveolar macrophages and it is important in the development of ALI. Stimulated alveolar macrophages produce NO, PGE₂ and pro-inflammatory cytokines, such as TNF-α, IL-6 and IL-1β (11,12). These cytokines play critical roles in the inflammatory responses that are featured in ALI and contribute to the severity of the lung injury (26-28). TNF-α, IL-6 and IL-1β amplify the entire, or focal, inflammatory responses as well as the recruitment of neutrophils into the lung in ALI (29). TNF-α, the earliest primary endogenous mediator of an inflammatory reaction, has been demonstrated to damage vascular endothelial cells and induce alveolar epithelial cells to produce other cell factors, such as IL-6 (30,31). TNF-α also elevates levels of intracellular ROS, which is an important factor in the pathogenesis of ALI. IL-6 is a product of TNF-α-induced epithelial cells and in ALI it is one of the most common inflammatory cytokines and it is also a significant predictor of morbidity and mortality in patients with ARDS (29). Moreover, IL-1β inhibits fluid transportations across the distal lung epithelium to cause surfactant disorders and to increase protein permeability across the alveolar-capillary barrier (32). In the present study, we determined that CA decreased TNF-α, IL-6, and IL-1β production compared with LPS-treatment alone. The inhibition of pro-inflammatory cytokine production was in accordance with the effects of CA on LPS-induced histological changes and ROS production. CA significantly suppressed the LPS-induced increase in ROS production in the BALF. CA administration also attenuated the extensive LPS-induced inflammatory responses in the lung tissues. These finding indicate that CA has protective effects on LPS instillation-induced ALI.

Previous studies (33,34) have indicated that pro-inflammatory cytokine production is modulated by the NF-κB signaling pathway. NF-κB is an important nuclear transcription factor that is responsible for inflammation, and it plays a critical role in regulating immune and inflammatory responses. In normal conditions, heterodimers of NF-κB complexes, which are mostly p50/p65, are present as an inactive cytoplasmic form with IκB in the cytoplasm (35,37). However, LPS stimulation is known to cause IκB phosphorylation by the IκB kinase complex, which results in degradation via the ubiquitin-proteasome pathway. IκB degradation leads to NF-κB dimer phosphorylation and translocation to the nucleus where it activates the transcription of specific target genes, including TNF-α, IL-1β, IL-6, COX-2 and PGE₂ (15-18). In patients with ALI, NF-κB activation increases pro-inflammatory cytokines, which promotes inflammatory responses and neutrophil recruitment into the lung (37). COX-2 expression, has also been demonstrated to increase inflammatory cells and induce the expression of prostaglandins, which aggravate inflammatory responses (38). In the present study, we investigated whether the anti-inflammatory activity of CA was exerted via the NF-κB signaling pathway, in the lung tissue of mice with ALI. In vivo, CA demonstrated a significant reduction in NF-κB phosphorylation and IκB degradation. In vitro, CA markedly decreased COX-2 expression and reduced PGE₂ production in LPS-stimulated RAW 264.7 cells. Thus, CA possesses anti-inflammatory activity in mice with ALI and LPS-stimulated RAW 264.7 cells. These effects are associated with downregulation of the NF-κB signaling pathway.

In conclusion, CA demonstrated effective suppression of the pro-inflammatory cytokines, ROS, NO and PGE₂ in LPS-stimulated RAW 264.7 cells and in mice with LPS-induced ALI. These effects were closely associated with the suppression of NF-κB phosphorylation. Thus, CA is a potential candidate for development as an adjunctive treatment for inflammatory disorders, such as ALI.
Acknowledgements

This study was supported by the grants from the Ministry of Science, ICT and Future Planning (FGC1011534) and the KRBB Research Initiative Program (KGM1221622) of the Republic of Korea.

References